News


JDP Initiates Pivotal Phase 3 Clinical Trial of JDP-205 for Acute Urticaria

May 30, 2017


European and Australian Patent Issuance to Extend Products' Global Protection

March 28, 2017


JDP Secures $17 Million in Series A Financing 
June 28, 2016

JDP Enters Development and Supply Agreement with Hospira/Pfizer 
March 24, 2016 

JDP Announces Notice of Allowance for Two New Patents Covering JDP-205 and JDP-207. 
July 20, 2015

JDP Announces Notice of Allowance for Its 4th Patent Covering JDP-205 
May 15, 2015 

JDP Successfully Completes Its Initial Phase 3 Clinical Trial of JDP-205 in Patients with Acute Urticaria Associated with an Acute Allergic Reaction.
January 8, 2015


JDP Therapeutics to Provide Corporate Update at 2015 Biotech ShowcaseTM in San Francisco. 
January 7, 2015
 
JDP Therapeutics Advanced as a Finalist for the CIRCLE OF EXCELLENCE Award by SmartCEO Magazine.
November 20, 2014
 
JDP Therapeutics Inc Presented at Forum 2014 Leadership Symposium 
April 28, 2014
 
JDP Receives U.S. FDA Clearance for Phase 3 Clinical Trial of JDP-205 in Patients with Acute Urticaria Associated with an Acute Allergic Reaction.  
March 12, 2014
 
Carlos A. Camargo, MD, DrPH, Joins JDP's Medical Advisory Board. 
December 2, 2013
 
First Patient Enrolled in Initial Phase III Clinical of JDP-205 Injection for the Treatment of Acute Urticaria.
July 12, 2013
 
JDP Announces Notice of Allowance for Its 3rd Patent Covering JDP-205.  
April 22, 2013
 
JDP in the Media: MedCity News.  
March 14, 2013
 
JDP to Present Phase I Clinical Data of JDP-205 at the 2013 AAAAI Conference.  
December 21, 2012
 
Dr. Benjamin Abella Joins JDP's Medical Advisory Board. 
October 16, 2012
 
Dr. Graham May Joins JDP Therapeutics as Chief Medical Officer.  
October 12, 2012
 
JDP Announces Notice of Allowance for Its 2nd Patent Covering JDP-205.
September 21, 2012
 
JDP Announces Notice of Allowance for U.S. Patent Covering JDP-205.  
July 12, 2012
 
JDP Appoints Sharon Clarke as Chief Business Officer.  
February 6, 2012
 
JDP Featured in BioCentury. 
January 9, 2012
 
JDP Therapeutics Announced Positive Phase One Results for JDP-207.  
November 1, 2011
 
JDP Therapeutics Featured in Start-Up Magazine.  
October 10, 2011
 
JDP Announces Appointment of Commercial/Business Advisor.  
September 28, 2011
 
JDP Therapeutics Establishes Medical Advisory Board. 
August 18, 2011 
 
JDP Therapeutics Reports Positive Phase One Results for Its Lead Candidate JDP-205. 
July 7, 2011
 
JDP Therapeutics Initiates Clinical Trial with Its Lead Candidate JDP-205.  
April 14, 2011
 
JDP Therapeutics Receives Regulatory Clearance to Conduct Clinical Trial on JDP-205.  
April 11, 2011
 
JDP Therapeutics Awarded $245,000 Therapeutic Discovery Grant.  
November 8, 2010
 
JDP Therapeutics Appointed Christopher M. Cashman to Board of Directors.  
May 28, 2010
 
JDP to Present at Canada-U.S. Partners in Biomedical Defense Conference.  
February 9, 2010
 
BIOWORLD TODAY Publishes Story on JDP Therapeutics.  
January 21, 2010
 
JDP to Present at Early Stage East 2009 Venture Conference (Princeton, NJ). 
November 25, 2009
 
Allergy Expert Dr. Robert M. Naclerio Serves as JDP's Allergy Advisor. 
August 24, 2009
 
JDP to Present at Mid Atlantic Diamond Ventures 2009. 
Jaunuary 21, 2009